| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802511501018 | 251150101 | TRAVATAN EY.DRO.SOL 40MC/ML FLX2,5ML | 8.46 | 8.87 | 12.22 |
| 05/2018 | 2802511501032 | 251150103 | TRAVATAN EY.DRO.SOL 40MC/ML BTx1 BOTTLE (LDPE) x 2,5ML | 8.46 | 8.87 | 12.22 |
Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.
Symptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.
Systemically absorbed when administered to the eye.
Terminal elimination half-life of travoprost free acid is 45 minutes.
Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid.